News-Suzhou Biosyntech Co., Ltd

Site Search siRNA Oligonucleotide Small nucleic acids

苏州贝信生物医药技术有限公司

Suzhou Biosyntech Co.,Ltd.

Current： Home > News

Pharmaceutical and Biological Industry: Small Nucleic Acid Technology, Large Market Space

2024-08-06 09:08:26

RNAi is a groundbreaking gene level therapy technology:RNAi technology can specifically eliminate or shut down the expression of specific genes, and therefore can be used to explore gene function and...

More +
RNA drugs have imaginative space

2024-08-06 09:08:18

Nature review: RNA drugs have room for imaginationAlthough RNA drug development has a history of 30 years, there are currently only a few RNA small molecule drugs on the global market: Vitravene (Fomi...

More +
Baran et al. Science: An idealized platform for oligonucleotide synthesis

2024-08-06 09:07:17

In traditional small molecule drug development, the determination of target specificity is often inseparable from the structural characteristics of DMPK (distribution, metabolism, and pharmacokinetics...

More +
Introduction of nucleosides into GNA/RNA improves siRNA drug activity in Nucleic Acid Research

2024-08-06 09:07:12

Off target effect is an important factor in the toxic side effects of nucleic acid drugs, and by introducing GNA into the seed region of siRNA drug guide chains, the stability of base pairing between...

More +
Small nucleic acid drugs, targeting the vast market of chronic diseases

2024-08-06 09:07:08

GalNAc (N-acetylglucosamine) coupling modification is currently a commonly used small nucleic acid drug delivery system.The three siRNA drugs recently launched are all modified with GalNAc, which is c...

More +
Summary excerpt: RNA interference (RNAi) as a novel therapeutic strategy for the treatment of chronic hepatitis B

2024-08-06 09:07:05

There are approximately 290 million chronic hepatitis B virus infections worldwide, and existing nucleoside (acid) analogues and interferon drugs cannot meet clinical needs due to long-term or even li...

More +

Every page shows 6 Article,Share 13 Article home Previous Page

123

2/3

Next Page last

Navigation

Oligonucleotide Oligonucleotide Conjugate Sercives About News Contact

Wechat Wechat

Wechat

Address：Room 601, 6th Floor, Building 7, Area B, Phase IV, Suzhou Biomedical Industrial Park, 108 Huayun Road, Industrial Park, Suzhou City, Jiangsu Province

Phone：+86-0512-53980886

Email：order@bsyntech.com

Copyright © Suzhou Biosyntech Co., Ltd All rights reserved record number：Su ICP No. 2024107123-1 Mainly engaged insiRNA,Oligonucleotide,Small nucleic acids, Welcome to inquire！
Technical Support： Suzhou Biosyntech Disclaimers

Site map | RSS | XML

新闻资讯

News News

RecommendRecommend

hot key wordsKeywords

ContactContact Us

Suzhou Biosyntech Co., Ltd

Orders Orders

Pharmaceutical and Biological Industry: Small Nucleic Acid Technology, Large Market Space

RNA drugs have imaginative space

Baran et al. Science: An idealized platform for oligonucleotide synthesis

Introduction of nucleosides into GNA/RNA improves siRNA drug activity in Nucleic Acid Research

Small nucleic acid drugs, targeting the vast market of chronic diseases

Summary excerpt: RNA interference (RNAi) as a novel therapeutic strategy for the treatment of chronic hepatitis B

Navigation

Suzhou Biosyntech Co., Ltd